Taskforce updates molnupiravir guidance following PANORAMIC trial results
2 December, 2022
The Taskforce has incorporated the preliminary results of the PANORAMIC trial into the body of evidence for oral antiviral molnupiravir (Lagevrio). This large (25,783 participants) open-label randomised controlled...
